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Aim. 18F-ﬂuorodeoxyglucose positron emission tomography (18F-FDG PET) is a powerful tool for staging and deﬁning “good
responders” to chemotherapy in tumor setting. Gastrointestinal stromal tumors (GISTs) are sarcoma involving gastrointestinal
tractandmayrequireachemotherapyincludingimatinib,atyrosinekinaseinhibitoragent.SomeGISTpatientsbecomerefractory
to imatinib; therefore, other tyrosine kinase inhibitors or concomitant chemotherapy may be considered for treatment. The aim
of this paper is to assess if 18F-FDG PET imaging is a useful tool to evaluate treatment response to new chemotherapies beyond
imatinib for GIST patients. Methods. We performed a review of the literature about the role of 18F-FDG PET in the evaluation of
treatment response to new chemotherapies beyond imatinib for GIST patients. Results and Conclusions. 18F-FDG PET seems to be
able to assess therapy response earlier than computed tomography (CT) imaging in imatinib refractory GIST patients treated with
other agents. However, a dual modality PET-CT imaging is recommendable to achieve a better detection of all lesions.
1.Introduction
Gastrointestinal stromal tumors (GISTs) are 0.1–3.0% of all
cancers involving gastrointestinal tract and account for 6%
of all sarcomas [1]. GISTs usually occur in middle-aged and
older patients and are often asymptomatic when <5cmin
their longest dimension; GISTs become symptomatic when
they grow >5cm of diameter [2]. Patients aﬀected by GISTs
are frequently symptomatic for gastrointestinal bleeding,
anemia, abdominal pain, dyspepsia, or an abdominal mass.
Most common localizations of GISTs are stomach (70%),
followed by the small intestine (20%), large intestine (5%),
and esophagus (<5%) [3]. GISTs are benign in 70% of cases,
but 30% are malignant and most common metastatic lo-
calizations occur in liver and peritoneum. Other metastatic
sites include the lungs, pleura, retroperitoneum, bone, and
subcutaneous tissues [1]. Prognostic factors have been pro-
posed as tumor size <5cm, ability to perform a complete
initial resection of the tumor, and tumor grade and site;
however, prediction of benign or malignant behavior of a
GISTremainsdiﬃculttoestablish[4],forexample,intestinal
tumors seem to be more malignant than gastric tumors
[5,6].Beyondtheprognosticstratiﬁcation,surgicalresection
remains the mainstay of treatment in resectable tumors,
whereas recurrent and metastatic GISTs are poor responders
to chemotherapy and irradiation.
TheoriginofGISTcellsisprobablyrelatednottosmooth
musclecellsbuttocellsofCajal[7,8].Infact,bothGISTcells
and cells of Cajal express, on the cell surface, the receptor c-
kitwhichisidentiﬁedbyCD117[9].C-kitisatyrosinekinase
and is activated as a ligand by a stem cell factor. A mutation
of the c-kit protooncogene activates the tyrosine kinase in
the absence of a stem cell factor and leads to uncontrolled
cell proliferation [10].2 ISRN Gastroenterology
Imatinib acts as a tyrosine kinase inhibitor of tumor
cells growth and resulted in an impressive response. To date,
imatinib represents the ﬁrst-line therapy in advanced GIST
[11]. In the last years, several trials have demonstrated the
eﬃcacy of imatinib in GIST patients by using diﬀerent imag-
ing modalities in the evaluation of treatment response such
as 18F-FDG PET and CT. 18F-FDG PET has been revealed
as a feasible tool for early assessment of therapy response in
GISTpatientstreatedwithimatinib,comparedwithCTscan.
However, the accuracy in detecting lesions is best achieved
with CT imaging; therefore, a dual modality PET-CT eval-
uation is recommendable at baseline and after adequate
treatment in patients with GIST [11–14].
Although imatinib improved survival of metastatic GIST
patients, imatinib resistance may emerge due most com-
monly to evolution of secondary c-kit mutations. Therefore,
new drugs have been proposed as alternative systemic thera-
pies in GIST patients once resistance or intolerance to imati-
nib appears, and the eﬃcacy of these agents have been evalu-
atedbythewell-establishedimagingtechniqueslike 18F-FDG
PET and CT.
Aim of this paper is to review literature data regarding
the role of 18F-FDG PET in evaluating treatment response to
otherconcomitantagentsorc-kitinhibitorsbeyondthewell-
known imatinib.
2. GISTandOther Chemotherapies beyond
Imatinib:The Role of 18F-FDGPETImaging
inAssessing TreatmentResponse
Maurel et al. investigated the role of 18F-FDG PET and/or
CT in the assessment of tumor response in GIST patients
whowererefractorytohigh-doseimatinibtreatmentandde-
signed a phase 1-2 trial of doxorubicin plus imatinib. Low-
dose chemotherapy combination showed promising activ-
ities, whereas PET and CT correlate poorly in this study.
However, in this study, evaluation of response by PET seems
to translate the eﬃcacy better than RECIST criteria [15],
and PET criteria (EORTC criteria [16]) correlate well with
progression-free survival [17].
Fuster et al. also evaluated the role of 18F-FDG PET
in assessing response to doxorubicin plus imatinib in GIST
patients refractory to high dose imatinib. Of 21 patients, 6
had partial response, 9 showed stable disease, and 6 expe-
rienced progression of disease according to EORTC criteria
[16] after 2 months of treatment. Poor concordance between
18F-FDG PET and CT was found. Moreover, a correlation
was demonstrated between PET response and progression-
free survival [18].
Demetri et al. designed an open-label study in GIST pa-
tients resistant or intolerant to imatinib who received suniti-
nib, an oral, multitargeted tyrosine kinase inhibitor. Clinical
beneﬁt was observed in 52 of the 97 patients, and a decrease
in tumor glycolytic activity was shown within 7 days of start-
ing sunitinib. For 67 patients (69%), 18F-FDG PET imaging
datawereavailablefrombaselinetoatleastonepost-baseline
scan. In 60 patients, PET imaging was performed after 1
week of sunitinib treatment and partial metabolic responses
to sunitinib were detected in 43 patients, as evidenced by a
decline in maximum standardized uptake value (SUVmax)
of ≥25% relative to baseline. Early changes in tumor me-
tabolism correlated with improved clinical outcome: most of
the43patientswithpartialmetabolicresponsessubsequently
showed clinical beneﬁt based on CT or magnetic resonance
imaging scans. However, objective responses on CT took
much longer to detect and evolved over several months, sim-
ilar to the pattern observed in studies of imatinib-treated
GIST patients [19].
Sunitinib was also tested by Prior et al. in 23 GIST
patients who experienced imatinib therapy failure and then
received one to 12 cycles of sunitinib therapy. Sunitinib was
taken orally for 4 weeks once a day, followed by a 2-week-
b r eakt op r o vid eat otalcy c lele ngtho f6w eeks.18F-FDG PET
was performed at baseline and after the ﬁrst 4 weeks of suni-
tinib administration. Contrast-enhanced CT was performed
at the end of each cycles. After 4 weeks of treatment, 18F-
FDGPETrevealedapartialmetabolicresponsein12patients
(52%), metabolically stable disease in seven patients (31%),
and metabolically progressive disease in four patients (17%).
Overall, 83% exhibited metabolic tumor control. Disease
progression was subsequently demonstrated by RECIST cri-
teria [15]inallpatientswithprogressivediseaseseenonPET.
These data suggested that early 18F-FDG PET performed
after the ﬁrst cycle of sunitinib treatment start may allow
the assessment of therapy response. However, this study had
some limitations like the small number of patients evaluated
[20].
Le Cesne et al. assessed the safety and eﬃcacy of a ﬁrst-
line therapy with masitinib, another tyrosine kinase inhibi-
tor, in 30 GIST patients. Metabolic response was evaluable
for 17/30 patients but 3 of these had a negative PET at
baseline. After 2 months of treatment, 3/14 had a complete
metabolicresponse,9/14hadpartialmetabolicresponse,and
2/14 had a stable metabolic disease. Collectively, metabolic
response using 18F-FDG PET was seen in 86% of patients,
whereasmasitinibinducedtumorresponsein20%ofevalua-
ble patients according to RECIST criteria [15]o nC Ti m a g e s .
As already reported, RECIST was not optimal compared to
EORTCcriteria[16] for an early response assessment of c-kit
inhibitors in GIST patients since the pattern of radiological
response had no prognostic value for further outcomes [21].
Benjamin et al. evaluated the role of motesanib, another
c-kit inhibitor, in advanced GIST patients who failed ima-
tinib treatment. Motesanib was taken 125mg orally once a
day for 48 weeks or until acceptable toxicity occured. Tumor
size and density were evaluated by CT at baseline and after
8, 16, 24, 32, 40, and 48 weeks, whereas metabolic tumor
activitywasassessedby 18F-FDGPETatbaselineand8weeks
after therapy start. Tumor response was deﬁned using differ-
ent methods including RECIST [15] and Choi criteria [22]
for CT images and EORTC criteria for PET [16]. EORTC
criteria and Choi criteria detected higher objective response
rates: these were 30% (in 91 evaluable cases) and 41% (in
102 evaluable cases), respectively. In this study, Choi criteria
seemed to be more sensitive in identifying PET responders
than RECIST criteria, since the latter detected only 3% of
response rate. However, compared to the current approvedISRN Gastroenterology 3
sunitinib, the insuﬃcient overall eﬃcacy did not support
further development of motesanib in GIST patients [23].
Lastly, Lassau et al. investigated the eﬃcacy of masatinib
therapy (7,5mg/kg daily by oral route) in metastatic GIST
patients by using several imaging techniques like dynamic
contrast-enhanced ultrasonography, CT, and 18F-FDG PET
imaging. CT scan was performed before treatment start and
2, 4, 6 weeks, and then every 3 months after treatment start;
18F-FDG PET was performed at baseline and 1 month after
treatment start. Of the 20 patients included in this study,
18F-FDG PET imaging was available for 14. After 1 month,
PET scan remained positive in 11/14 (78.6%): no change
in standard uptake values (SUV) was recorded at 1 month
in 4 patients, whereas an important reduction in SUV was
recorded in the remaining 7 patients. These data conﬁrmed
that 18F-FDG PET imaging seems to be the gold standard for
early assessment of tumor response not only to imatinib but
also to other c-kit inhibitors, as masatinib, in GIST patients
[24].
3. Conclusion
Intolerance or resistance to imatinib may occur in GIST
patients after treatment start and often progression of the
disease is observed once the therapy is stopped. For these
reasons, in the last years other new c-kit inhibitors or dif-
ferent concomitant treatments are emerging as an alternative
chemotherapy in GIST patients with advanced disease.
18F-FDG PET has become the gold standard for early as-
sessment of tumor response to imatinib and seemed to have
the same role in evaluating other c-kit inhibitors response.
CThasmoreaccuracyindetectinglesionsbutmorphological
imaging alone may reveal therapy response several months
after treatment start. For all these reasons, a dual modality
PET-CT scan is recommended in staging and re-evaluating
GIST patients who undergo c-kit inhibitors therapy as well
as imatinib.
On the other hand, fewer data are available from liter-
ature and further clinical trials are needed to establish the
eﬃcacy of these new chemotherapies in GIST patients by
using 18F-FDG PET imaging.
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